Geode Capital Management
TRAX

Geode Capital Management’s First Tracks Biotherapeutics TRAX Stock Holding History

Geode Capital Management’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.1M Buy
+702,087
New +$13.1M ﹤0.01% 2351

Other funds holding TRAX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
FEG
Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Geode Capital Management's TRAX Position: Q2 2026 in Review

Geode Capital Management opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 702,087 shares worth $14.1M. The stake represents ﹤0.01% of the portfolio and ranks #2351 among its holdings.

66 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Geode Capital Management held 702,087 shares of First Tracks Biotherapeutics worth $14.1M as of Q2 2026.
  • First Tracks Biotherapeutics was a new Geode Capital Management position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2351 holding.
  • 66 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.